Market open
BioMarin/$BMRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioMarin
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Ticker
$BMRN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
3,040
ISIN
US09061G1013
Website
BioMarin Metrics
BasicAdvanced
$11B
21.70
$2.71
0.30
-
Price and volume
Market cap
$11B
Beta
0.3
52-week high
$94.85
52-week low
$52.93
Average daily volume
1.9M
Financial strength
Current ratio
5.52
Quick ratio
3.202
Long term debt to equity
10.281
Total debt to equity
10.281
Interest coverage (TTM)
59.71%
Management effectiveness
Return on assets (TTM)
6.38%
Return on equity (TTM)
9.64%
Valuation
Price to earnings (TTM)
21.698
Price to revenue (TTM)
3.791
Price to book
1.94
Price to tangible book (TTM)
2.1
Price to free cash flow (TTM)
18.036
Growth
Revenue change (TTM)
19.36%
Earnings per share change (TTM)
152.82%
3-year revenue growth (CAGR)
16.22%
3-year earnings per share growth (CAGR)
132.76%
What the Analysts think about BioMarin
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BioMarin stock.
BioMarin Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BioMarin Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BioMarin News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BioMarin stock?
BioMarin (BMRN) has a market cap of $11B as of May 15, 2025.
What is the P/E ratio for BioMarin stock?
The price to earnings (P/E) ratio for BioMarin (BMRN) stock is 21.7 as of May 15, 2025.
Does BioMarin stock pay dividends?
No, BioMarin (BMRN) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next BioMarin dividend payment date?
BioMarin (BMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for BioMarin?
BioMarin (BMRN) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.